BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded down 6.6% during mid-day trading on Friday . The company traded as low as $7.38 and last traded at $7.38. 518,761 shares changed hands during mid-day trading, a decline of 30% from the average session volume of 740,190 shares. The stock had previously closed at $7.90.
BCRX has been the topic of several recent research reports. BidaskClub cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. Finally, Royal Bank of Canada lifted their target price on shares of BioCryst Pharmaceuticals to $16.00 and gave the stock a “positive” rating in a research note on Tuesday, December 4th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. BioCryst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $12.18.
The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.62 and a current ratio of 1.65. The company has a market capitalization of $813.11 million, a PE ratio of -7.53 and a beta of 1.81.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, March 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 490.25% and a negative return on equity of 175.83%. The company had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $2.39 million. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.
In other news, VP Lynne Powell sold 3,046 shares of the business’s stock in a transaction dated Wednesday, January 16th. The shares were sold at an average price of $9.27, for a total transaction of $28,236.42. Following the transaction, the vice president now owns 3,046 shares of the company’s stock, valued at approximately $28,236.42. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Thomas R. Staab II sold 5,000 shares of the business’s stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $9.85, for a total transaction of $49,250.00. Following the transaction, the chief financial officer now directly owns 133,426 shares in the company, valued at approximately $1,314,246.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,000 shares of company stock worth $279,663. 4.50% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the company. Paloma Partners Management Co acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $84,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $122,000. Amalgamated Bank acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $122,000. Legal & General Group Plc boosted its position in shares of BioCryst Pharmaceuticals by 14.5% during the 4th quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 2,453 shares during the last quarter. Finally, Ibex Investors LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $216,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2019/03/24/biocryst-pharmaceuticals-bcrx-stock-price-down-6-6.html.
BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Read More: Discover Your Risk Tolerance
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.